No Data
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): From January to September 2024, the sales revenue of "Artemisia annua pollen allergen sublingual drop" was 20.5705 million yuan, a year-on-year increase of 87.53%.
Gelonghui, on January 13, announced that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) recently stated in an investor relations activity that from January to September 2024, the sales revenue of the company's product "Artemisia annua pollen allergen sublingual drops" reached 20.5705 million yuan, an increase of 87.53% compared to the same period last year. The rapid growth in sales revenue of the "Artemisia annua pollen allergen sublingual drops" is primarily due to the company's increased promotional efforts in the northern market.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): The research projects for stem cell drugs include relevant indications for degenerative diseases, currently in the preclinical research stage.
On January 13, Gelonghui reported that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) recently mentioned in investor relations activities that the company's stem cell drug research projects include indications related to degenerative diseases, which are currently in the preclinical research stage. The company will continue to carry out research and development in the field of stem cell drugs.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) equity distribution for the first three quarters of 2024: 1 yuan for every 10 shares, with the equity registration on January 9.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that the plan for equity distribution for the first three quarters of 2024 is as follows: to the public...
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) has obtained the high-tech enterprise certification.
Gelonghui December 31st丨Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that the company recently received the "High-tech Enterprise Certificate" issued jointly by the Zhejiang Provincial Department of Economy and Information Technology, the Zhejiang Provincial Department of Finance, and the State Administration of Taxation Zhejiang Provincial Taxation Bureau. The certificate number is GR202433011726, and it is valid for three years.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) has obtained registration certificates for three types of skin prick test allergenic extracts including sweet gum pollen.
Gelonghui reported on December 23 that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that it has recently obtained the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The company submitted registration for three skin prick liquid products: "Sycamore Pollen Allergen Skin Prick Liquid," "German Cockroach Allergen Skin Prick Liquid," and "Cat Dander Allergen Skin Prick Liquid," which have been approved for market launch. The three skin prick liquid products, including the Sycamore Pollen Allergen Skin Prick Liquid, are related to the company's already launched "Dust Mite Skin Prick Diagnostic Kit" (National Drug Approval Number S20080010) and "House Dust Mite Skin Prick Diagnostic Kit."
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 29% Price Boost Is Out Of Tune With Earnings
